Rodríguez-Martín M, Sáez-Rodríguez M, García-Bustínduy M, Martín-Herrera A, Noda-Cabrera A
Department of Dermatology, Hospital Universitario de Canarias, University of La Laguna, La Laguna, Tenerife, Spain.
Dermatol Online J. 2008 Nov 15;14(11):14.
Proteasome inhibitors are emerging as a promising class of anti-cancer therapeutic agents. Bortezomib (PS341) is the first proteosome inhibitor with clinical significance. It acts by blocking vital functions of tumoral cells in myeloma, inducing apoptosis. Its toxicity is usually manageable. Gastrointestinal symptoms, peripheral neuropathy, neuropathic pain and thrombocytopenia are described as the most common side effects. We report on a case of cutaneous lesions induced by bortezomib in a patient with relapsed multiple myeloma (MM).
蛋白酶体抑制剂正逐渐成为一类有前景的抗癌治疗药物。硼替佐米（PS341）是首个具有临床意义的蛋白酶体抑制剂。它通过阻断骨髓瘤肿瘤细胞的重要功能发挥作用，诱导细胞凋亡。其毒性通常易于控制。胃肠道症状、周围神经病变、神经性疼痛和血小板减少被描述为最常见的副作用。我们报告了1例复发多发性骨髓瘤（MM）患者由硼替佐米引起的皮肤病变病例。
